Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > FDA approval
View:
Post by Solid1 on Apr 29, 2024 5:53am

FDA approval

Let's not kid ourselves, the big hit is FDA approval 
From then on, no more PR is needed - it will spread quickly.
But the wait is already driving you a bit crazy :-D 
Comment by QContinuum1 on Apr 29, 2024 8:17am
Don't know if ANDA approval is coming any time soon given the recent-ish judge ruling.  I think nearer term is Brazil, their partner and what all that means.  Between Germany and Brazil, those two jurisdictions alone ought drive positivity and not by a small measure. What the ends up doing to the SP is anyone's guess mind you.  But certainly, if LABS gets a ruling/FDA gift, ...more  
Comment by Starkicker on Apr 29, 2024 9:30am
I'm going to be watching the Q1 numbers and report closely in a couple of weeks. If there isn't a significant uptick in revenue I'll reasses my interest in this company. When management says things like they did back in November then nothing happens, I have to question their authenticity and my investment.
Comment by QContinuum1 on Apr 29, 2024 11:24am
Agreed.  I would also argue that we were also told many a thing at the YE call which now they need to make good on. I get the mgmt double talk and all of that, but they have made commitments and statements leading up to this (and realistically the next couple) call(s) and they need now execute. The time for words and blather is over, they have all the need to make the SP organically ...more  
Comment by subaru1i on Apr 29, 2024 9:41am
TWO, 2, FDA approvals.   One for generic Epidiolex as already mentioned by CEO to be launched in the U.S. and 1 for 'new drug', the 505(b)2.   TWO FDA APPROVALS.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities